U.S. Markets closed

Seattle Genetics, Inc. (SGEN)

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
Add to watchlist
55.02+0.51 (+0.94%)
At close: 4:00PM EDT

54.84 -0.18 (-0.32%)
After hours: 4:41PM EDT

People also watch
IMGNBMRNINCYALNYCLDX
  • I'm more interested in the Q2 CC than any I have been since the pre-approval Adcetris days. I don't expect any hard news as I can't recollect a time that Siegall announced POSITIVE hard news at a CC. I do recollect his announcing negative news, however, the discontinuation of SGN-40 (?) comes to mind. When it comes to positive news we are usually left with trying to read the "tea leaves" in his commentary. That being said, for me it will be interesting to hear what he has to say about the pipeline outside of Adcetris. Are the cd 33 efforts still alive? Is there reason to believe their technology is robust in other areas?How strong will his comments be in these areas? If it's essentially all Adcetris all the time, at least for the foreseeable future, it may soon be time to move on.

    Paladin
  • Seattle and Genentech in collaboration on LIV1A in TNBC

    http://www.businesswire.com/news/home/20170724005400/en/Seattle-Genetics-Announces-Clinical-Collaboration-Expand-Therapeutic

    Seattle Genetics Announces Clinical Collaboration to Expand the Therapeutic Evaluation of SGN-LIV1A in Triple Negative Breast Cancer
    Seattle Genetics, Inc. (Nasdaq: SGEN), a global biotechnology company, today announced a clinical collaboration agreement with Genentech, a member of
    www.businesswire.com
  • [!] Option spread traders have a look at CreditSpreads.io, absolutely free live feed of mathematically profitable option credit spreads for the coming month, sometimes including spreads for SGEN! High probability option credit spreads provide a method to invest with defined risk and the max profit received up front. CreditSpreads.io targets solely the option spreads which meet its stringent criteria for probability and profit, and contributes to sustained profitability by alerting you of any impending situations which can affect the trade. http://www.creditspreads.io

    CreditSpreads.io
    Sustainable, high probability, defined risk stock option trading opportunities.
    www.creditspreads.io
  • Have held this stock for many years. Sold off a smaller portion recently to take a profit. Any opinions on 1-2 year prospects in view of recent sgn-33a discontinuation and less than riveting Echelon-1 results? Do these recent developments make a buyout over this period more or less likely?....and at what level?

    I welcome well thought out speculation and observations. Thanks!
  • SGEN in a great position to day trade again. Load the boat! $20.00 off it's high. When JUNO tanked it was also a sure thing. Already gained back 10 bucks off its low. These bio stocks can be huge money makers if you SELL on the rapid rise and re-enter on huge dips. Remember BLUE?
  • SGEN bottom is in. Let's look for a turn around after earning report. Exciting news is near the end of the year and early next year.
    Have a great week!
  • SGEN bought Clay a pretty impressive home with all those free shares. I posted on this board a couple years ago about bio tech company CEO's homes and many of those so called bio tech's are banko. Remember the one I posted where the house slid down this hill? SGEN is not one of those scam startups so that is not what I am saying so Red, save the ink.
  • WIll ride this one all year.
  • Well, we may be hurting a bit lately. But thank god, Clay can still feed his family. He made a cool $924,000 this week through his latest round of options sales.
  • SEAGEN reported a 8.2% stake in IMMU.
  • What kills me about SGEN is their long history of poor messaging. The recent E-1 press release and conference call were a disaster. In the press release they highlighted neutropenia and neuropathy as toxs associated with introduction of the ADC into frontline but make no mention of the reduced pulmonary tox associated with removal of bleomycin only an increased risk in the control arm. The first two toxs have always been associated with Adcetris and as you know clear rapidly after treatment cessation. The pulmonary tox is scarring and lasts a lifetime. Why highlight it the first two toxicities they are already known? The first thing the media does is talk about new toxicities instead of highlighting the reversal of pulmonary tox. It’s a huge misstep and completely changed the sentiment of the press release to the media and traders.
    They also fail to highlight their collaborators success. They have a breakthrough designation in Europe for DLBCL and it was never mentioned. I had to dig it up and highlight it on the board. They must have known that was coming. It could have even been mentioned the E-1 press release.
    The executive committee has a duty to properly frame the messaging of their important improvements of their life saving therapies. It’s not as if they are making stuff up to goose the stock. They just need to highlight the actual data.
    It's almost as if they want the stock price to be suppressed. It's like Clay is purposefully disregarding his fiduciary duties to get lower share prices for options. I can't figure it out. At this point it's either gross incompetence or criminally negligent.
  • If it sinks to $50, time to unload big time.
    Relative strength is poor
  • Marriage is the triumph of imagination over intelligence. http://dataunion.tistory.com/3192

    Seattle Genetics NASDAQ : SGEN Correlation Histogram
    X axis : Stocks Price Correlation Coefficient Y axis : Quantity of stocks May-2016 1,000 Day Parameter 2,830 NASDAQ Stocks Price Analysis This stock mode of correlation coefficient is 0.5 In other words, the correlation coefficient of the other stock
    dataunion.tistory.com
  • Is management going to allow the shorts to bleed the share price below $50 on low volume?
    I hope they wake up soon.
    Kool
  • The posters on this board for the last 3 years were saying this was going to be bought out at $70.00 a share. When the stock finally reached $70.00 (the big goal) you still held?
  • Genentech's ADC 79b in DLBCL utilizing SGENs linker got Prime Status at the EMA. Similar to FDAs breakthrough designation.
    Roche's (RHHBY) Leukemia Drug Gets Prime Status in EU
    The European Medicines Agency (EMA) granted PRIME (PRIorityMEdicines) designation to Roche Holdings AG 's RHHBY investigational drug polatuzumab.
    www.nasdaq.com
  • Echelon results are out. No 90% or greather but 82% without lung issue (long term terrible from personal knowledge) is still very good. Market reaction is same as when Adcetris received initial FDA approval. CC is either 8:30 this AM (Forbes) or 5:30 this PM (AP)
    Talking about snatching defeat from the jaws of victory.
    Kool
  • We hv heard from Red yet.
    Are you still here?
    Kool
  • Whomever is buying now is going to make a lot of dough in a couple of days.
    Kool
  • New adcetris data in GVHD. "BV is tolerable and has activity in steroid-refractory acute GVHD and merits further
    investigation. " Big market.

    http://www.bloodjournal.org/content/early/2017/05/04/blood-2017-03-772210